Ann: Further commercial milestones achieved in Spain, page-26

8. Investigate device usage
in other solid tumour indications, potentially via strategic partnership

Deliverables

• Identify potential use of the OncoSilTM device in other solid tumours.

• Identify suitable industry partners to assist in further development of the device outside of the current approved indication.

From the Investor presentation in August 2022. Also hopefully still progressing the FDA regarding possible Bile Duct treatment . Hence my comments from my post from the 24th of April. It is important for others to be reminded about what has been actually been published by the company. Who knows where the device may lead with other solid tumours.